Probiotics to prevent gastrointestinal toxicity from cancer therapy: An interpretive review and call to action

Matthew A. Ciorba, Christopher Hallemeier, William F. Stenson, Parag J. Parikh

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Purpose of review There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward. Recent findings Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials. Summary No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question.

Original languageEnglish (US)
Pages (from-to)157-162
Number of pages6
JournalCurrent opinion in supportive and palliative care
Volume9
Issue number2
DOIs
StatePublished - Jun 6 2015

Fingerprint

Gastrointestinal Neoplasms
Probiotics
Clinical Trials
Pelvic Neoplasms
Mucositis
Enteritis
Lactobacillus
Therapeutics
Radiotherapy
Drug Therapy
Population

Keywords

  • diarrhea
  • fluorouracil
  • metabolome
  • microbiota
  • prebiotic
  • probiotics

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Critical Care and Intensive Care Medicine

Cite this

Probiotics to prevent gastrointestinal toxicity from cancer therapy : An interpretive review and call to action. / Ciorba, Matthew A.; Hallemeier, Christopher; Stenson, William F.; Parikh, Parag J.

In: Current opinion in supportive and palliative care, Vol. 9, No. 2, 06.06.2015, p. 157-162.

Research output: Contribution to journalReview article

@article{a597318f7bb94945be9300b7299befff,
title = "Probiotics to prevent gastrointestinal toxicity from cancer therapy: An interpretive review and call to action",
abstract = "Purpose of review There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward. Recent findings Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials. Summary No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question.",
keywords = "diarrhea, fluorouracil, metabolome, microbiota, prebiotic, probiotics",
author = "Ciorba, {Matthew A.} and Christopher Hallemeier and Stenson, {William F.} and Parikh, {Parag J.}",
year = "2015",
month = "6",
day = "6",
doi = "10.1097/SPC.0000000000000134",
language = "English (US)",
volume = "9",
pages = "157--162",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Probiotics to prevent gastrointestinal toxicity from cancer therapy

T2 - An interpretive review and call to action

AU - Ciorba, Matthew A.

AU - Hallemeier, Christopher

AU - Stenson, William F.

AU - Parikh, Parag J.

PY - 2015/6/6

Y1 - 2015/6/6

N2 - Purpose of review There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward. Recent findings Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials. Summary No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question.

AB - Purpose of review There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward. Recent findings Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials. Summary No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question.

KW - diarrhea

KW - fluorouracil

KW - metabolome

KW - microbiota

KW - prebiotic

KW - probiotics

UR - http://www.scopus.com/inward/record.url?scp=84946165965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946165965&partnerID=8YFLogxK

U2 - 10.1097/SPC.0000000000000134

DO - 10.1097/SPC.0000000000000134

M3 - Review article

C2 - 25872116

AN - SCOPUS:84946165965

VL - 9

SP - 157

EP - 162

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 2

ER -